EnzymeBioSystems 10-Q 8 May 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2018	May 04, 2018
Document And Entity Information
Entity Registrant Name	EnzymeBioSystems
Entity Central Index Key	1,471,968
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,592,010
Trading Symbol	ENZB
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018

Condensed Interim Balance Sheet

Condensed Interim Balance Sheets - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Current assets:
Cash and cash equivalents	$ 391,421	$ 41,249
Prepaid expense		3,000
Total current assets	391,421	44,249
TOTAL ASSETS	391,421	44,249
Current liabilities:
Accounts payable	2,600	100
Accrued expenses		4,000
Total current liabilities	2,600	4,100
Total Liabilities	2,600	4,100
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, 2,125,000 and 125,000 shares of Series A Preferred Stock issued and outstanding as of March 31, 2018 and June 30, 2017, respectively	2,125	125
Common stock, $0.001 par value, 195,000,000 shares authorized, 5,592,010 and 832,235 shares issued and outstanding as of March 31, 2018 and June 30, 2017, respectively	5,592	832
Additional paid-in capital	2,208,738	1,261,543
Accumulated deficit	(1,827,634)	(1,222,351)
Total stockholders’ equity	388,821	40,149
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 391,421	$ 44,249

Condensed Interim Balance Shee3

Condensed Interim Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Oct. 19, 2017	Jun. 30, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001		$ 0.001
Preferred stock, shares authorized	5,000,000		5,000,000
Series A Preferred stock, shares issued	2,125,000		125,000
Series A Preferred stock, shares outstanding	2,125,000		125,000
Common stock, par value	$ 0.001		$ 0.001
Common stock, shares authorized	195,000,000		195,000,000
Common stock, shares issued	5,592,010	16,641,822	832,235
Common stock, shares outstanding	5,592,010	16,641,822	832,235

Condensed Interim Statements of

Condensed Interim Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenue
Operating expenses:
Officers' compensation (including stock- based compensation of $0, $0, $398,000 and $0 respectively)	11,000	18,000	450,000	54,000
Professional Fees	15,500	10,825	37,830	28,325
Investor Relations			99,200
Other	7,475	3,895	19,194	6,979
Total operating expenses	33,875	32,720	606,224	89,304
Loss from operations	(33,875)	(32,720)	(606,224)	(89,304)
Other income (loss)
Restitution from former officer	200		900
Interest income	41		41
Proceeds from sale of subsidiary		25,000		25,000
Consulting fees relating to sale of subsidiary		(10,000)		(10,000)
Other income (loss)- net	241	15,000	941	15,000
Net (Loss)	$ (33,734)	$ (17,720)	$ (605,283)	$ (74,304)
Weighted average number of common shares outstanding - basic and diluted	5,592,010	832,235	3,397,369	832,235
Net loss per common share - basic and diluted	$ (0.01)	$ (0.03)	$ (0.18)	$ 0

Condensed Interim Statements o5

Condensed Interim Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Stock-based compensation	$ 0	$ 0	$ 398,000	$ 0

Condensed Interim Statements o6

Condensed Interim Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
OPERATING ACTIVITIES
Net Loss	$ (605,283)	$ (74,304)
Adjustments to reconcile net loss to net cash used by operating activities:
Stock-based compensation	398,000	0
Changes in operating assets and liabilities
Prepaid expenses	3,000
Accounts payable	2,500
Accrued expenses	(4,000)
Cash (used) by operating activities	(205,783)	(74,304)
FINANCING ACTIVITIES
Proceeds from sale of Units	551,955
Proceeds from sale of common stock to former chief executive officer	2,000
Proceeds from sale of Class A Preferred Stock to Berkeley Clinic, L.C.	2,000
Net cash provided by financing activities	555,955
NET INCREASE (DECREASE) IN CASH	350,172	(74,304)
CASH - BEGINNING OF THE PERIOD	41,249	140,042
CASH - END OF THE PERIOD	391,421	65,738
SUPPLEMENTAL DISCLOSURES:
Interest paid
Income taxes paid

Condensed Interim Financial Sta

Condensed Interim Financial Statements	9 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Interim Financial Statements	NOTE 1 - CONDENSED INTERIM FINANCIAL STATEMENTS The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2018 and for all periods presented have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2017 audited financial statements. The results of operations for the period ended March 31, 2018 are not necessarily indicative of the operating results for the full year. Basis of Presentation In the opinion of management, the accompanying balance sheets and related interim statements of operations and cash flows include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Preparing financial statements requires management to make estimates and assumptions the affect the reported amounts of assets, liabilities, revenue and expenses. Actual results and outcomes may differ from management’s estimates and assumptions. Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Form 10-K. Reverse Stock Split Effective October 19, 2017, the Company effected a 1-for-20 reverse stock split of its common stock (which reduced the issued and outstanding shares of common stock from 16,641,822 shares to 832,235 shares) and its Series A Preferred Stock (which reduced the issued and outstanding shares of Series A Preferred Stock from 2,500,000 shares to 125,000 shares). The accompanying financial statements retroactively reflect this reverse stock split.

Going Concern

Going Concern	9 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 - GOING CONCERN These condensed financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of March 31, 2018, the Company has not recognized any revenues and has accumulated losses of approximately $(1,827,634) since inception. The Company’s ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and its ability to achieve and maintain profitable operations. Management plans to raise equity capital to finance the operating and capital requirements of the Company. Amounts raised will be used to further develop the Company’s products, to provide financing for marketing and promotion, to secure property and equipment, and for other working capital purposes. While the Company is putting forth its best efforts to achieve the above plans, there is no assurance that any such activity will generate sufficient funds necessary to continue operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might arise from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue recognition The Company will apply the provisions of ASC 605, Revenue Recognition (“ASC 605”). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to March 31, 2018, the Company has not recognized any revenues. Recent accounting pronouncements On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance is effective for annual periods beginning after December 15, 2018; early adoption is permitted. The Company has early adopted ASU 2017-11. As a result, we have not recognized the fair value of the warrants containing down round features that were issued in the Private Offering from September 2017 to December 2017 (see Note 4) as liabilities. Ce a i acco nti g pronounce en s e bee ss d by t e S d o e ta a se t g rga za io s w i c h a re n t yet e fec ive a d t efo e h ve not ye ee a o e b the Co a . e mpac o t Co any’s fi a c a l os o nd e su s of ope ations f om dop t on of ese standar s is not expec e t be a er al .

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Stockholders' Equity	NOTE 4 - STOCKHOLDERS’ EQUITY The Company is authorized to issue up to 5,000,000 shares of its $0.001 par value preferred stock and up to 195,000,000 shares of its $0.001 par value common stock. The shares of Series A Preferred Stock carry a voting weight equal to 10 shares of common stock per share of Series A Preferred Stock, are not redeemable, and cannot be converted into Common Shares unless it is approved by the Board of Directors and agreed upon by the Series A Preferred Shareholders. The shares of Series A Preferred stock have no dividend rights but have a liquidation preference for funds paid for the Series A Preferred Stock shares. From September 2017 to December 2017, the Company conducted a Private Offering with accredited investors to help fund the Company. The Company offered up to 3,750,000 Common Units at a price of $0.20 per Unit. Each Unit consists of one share of post reverse stock split common stock, one Class A warrant exercisable at $0.30 per share of post reverse stock split common stock, one Class B warrant exercisable at $0.40 per share of post reverse stock split common stock and one Class C warrant exercisable at $0.60 per share of post reverse stock split common stock. The Offering provided that Berkeley Clinic, L.C. (“Berkeley”) (holder of 75,000 shares of Common Stock and 125,000 shares of Series A Preferred Stock prior to Berkeley’s purchase of 2,000,000 shares of Series A Preferred Stock discussed in the fourth succeeding paragraph below) would maintain the same 63.6% voting control of the Company that it held prior to the Offering. The offering and sale of the Units in the Offering were exempt from registration under the Act by virtue of Section 4(2) of the Act, and Rule 506. From September 6, 2017 to December 12, 2017, we sold a total of 2,759,775 Common Units to 16 investors at a price of $0.20 per Unit for gross proceeds of $551,955. The Class A, Class B and Class C warrants all expire August 31, 2022, and all provide for the reduction of their exercise prices if we directly or indirectly sell or grant any right with respect to our common stock or common stock equivalents at an effective price lower than the current exercise price of any of the Class A warrants. Holders that exercise Class C warrants will receive Class D cashless warrants to receive additional shares of common stock at no cost in the event that the closing price of the common stock on the business day immediately prior to the date of exercise exceeds $0.40 per share. On November 29, 2017, Gary Rojewski, the former CEO of the Company from June 2, 2014 to December 27, 2017, purchased 2,000,000 shares of unregistered restricted common stock in exchange for $2,000 cash. Mr. Rojewski was entitled to purchase these shares based on past services rendered the Company. The Company recognized officers’ compensation expense in the amount of $398,000, which represents the excess of the $400,000 estimated fair value of the 2,000,000 shares of common stock (using the $0.20 per share price used in the Private Offering) over the $2,000 purchase price. On December 29, 2017, Berkeley Clinic, L.C. purchased 2,000,000 Shares of Series A Preferred Stock for $2,000, to maintain voting control of the Company, as was required pursuant to the Private Offering discussed in the fourth preceding paragraph above.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 5 - RELATED PARTY TRANSACTIONS On September 17, 2017, the Company organized a Nevada corporation named LCNS as a subsidiary of the Company. On September 29, 2017, LCNS sold 2,000,000 restricted shares of LCNS common stock to T. J. Jesky (1,000,000 shares) and Mark DeStefano (1,000,000 shares) at a price of $0.005 per share and $10,000 was deposited in LCNS’s attorney’s client trust account. Jesky and DeStefano are members of Berkeley Clinic, L.C. (See Note 4). The sole officer and director of the Company is involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts.

Provision for Income Taxes

Provision for Income Taxes	9 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Provision for Income Taxes	NOTE 6 – PROVISION FOR INCOME TAXES The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal income tax rate to income (loss) before provision for income taxes. The sources and tax effects of the differences are as follows: Nine Months Ended March 31, 2018 2017 Expected tax at 35% $ (211,849 ) $ (26,006 ) Non-deductible stock based compensation 139,300 - Remeasurement of deferred income tax assets from 35% to 21%(a) 200,149 - Increase (decrease) in valuation allowance (127,600 ) 26,006 Provision for (benefit from) income taxes $ - $ - (a) As a result of the Tax Cuts and Jobs Act enacted on December 22, 2017, the United States corporate income tax rate is 21% effective January 1, 2018. Accordingly, we have reduced our deferred income tax asset relating to our net operating loss carryforward (and the valuation allowance thereon) by $200,149 from $500,372 to $300,223 as of March 31, 2018. Deferred tax assets as of March 31, 2018 and June 30, 2017 are calculated as follows: March 31, 2018 June 30, 2017 Deferred tax assets: Net operating loss carry forward 300,223 $ 427,823 Less: valuation allowance (300,223 ) (427,823 ) Net deferred tax assets $ - $ - Based on management’s present assessment the Company has not yet determined if to be more likely than not that a deferred tax asset of $300,223 attributable to the future utilization of the $1,429,634 net operating loss carryforward as of March 31, 2018 will be realized. Accordingly, the Company has provided a 100% valuation allowance against the deferred tax asset in the financial statements at March 31, 2018. The Company will continue to review this valuation allowance and make adjustments as appropriate. The net operating loss carryforward of approximately $1,429,634 at March 31, 2018 and approximately $1,222,351 at June 30, 2017 expires commencing in year 2029. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations. Should a significant change in ownership occur, net operating loss carryforwards may be limited as to use in the future. The Company has no tax positions. All tax years remain subject to examination by taxing jurisdictions.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 7 - COMMITMENTS AND CONTINGENCIES On February 16, 2018, the Securities and Exchange Commission announced the temporary suspension of trading in the Company’s securities from February 20, 2018 to March 5, 2018 because of questions regarding the accuracy of information in filings with the Commission, including a Form S-1 filed on January 11, 2018, a Form 8-K filed on January 4, 2018 and Forms 10-K filed on September 20, 2016 and October 13, 2017 for the fiscal years ended June 30, 2016 and 2017, respectively, concerning among other things, the Company’s business operations and identity of its officers. On March 12, 2018, Her Imports (“HER”) filed a legal action against the Company in connection with the Company’s sale of a subsidiary to HER in 2017 for $25,000 cash. The action seeks recovery of the $25,000, legal fees and certain specific damages that HER claims they incurred. The Company believes that the claims have no merit and intends to vigorously defend itself against this action.

Significant Accounting Polici14

Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	Revenue recognition The Company will apply the provisions of ASC 605, Revenue Recognition (“ASC 605”). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to March 31, 2018, the Company has not recognized any revenues.
Recent Accounting Pronouncements	Recent accounting pronouncements On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance is effective for annual periods beginning after December 15, 2018; early adoption is permitted. The Company has early adopted ASU 2017-11. As a result, we have not recognized the fair value of the warrants containing down round features that were issued in the Private Offering from September 2017 to December 2017 (see Note 4) as liabilities. Ce a i acco nti g pronounce en s e bee ss d by t e S d o e ta a se t g rga za io s w i c h a re n t yet e fec ive a d t efo e h ve not ye ee a o e b the Co a . e mpac o t Co any’s fi a c a l os o nd e su s of ope ations f om dop t on of ese standar s is not expec e t be a er al .

Provision for Income Taxes (Tab

Provision for Income Taxes (Tables)	9 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) Before Provision for Income Taxes	The sources and tax effects of the differences are as follows: Nine Months Ended March 31, 2018 2017 Expected tax at 35% $ (211,849 ) $ (26,006 ) Non-deductible stock based compensation 139,300 - Remeasurement of deferred income tax assets from 35% to 21%(a) 200,149 - Increase (decrease) in valuation allowance (127,600 ) 26,006 Provision for (benefit from) income taxes $ - $ - (a) As a result of the Tax Cuts and Jobs Act enacted on December 22, 2017, the United States corporate income tax rate is 21% effective January 1, 2018. Accordingly, we have reduced our deferred income tax asset relating to our net operating loss carryforward (and the valuation allowance thereon) by $200,149 from $500,372 to $300,223 as of March 31, 2018.
Schedule of Deferred Tax Assets	Deferred tax assets as of March 31, 2018 and June 30, 2017 are calculated as follows: March 31, 2018 June 30, 2017 Deferred tax assets: Net operating loss carry forward 300,223 $ 427,823 Less: valuation allowance (300,223 ) (427,823 ) Net deferred tax assets $ - $ -

Condensed Interim Financial S16

Condensed Interim Financial Statements (Details Narrative) - shares	Oct. 19, 2017	Mar. 31, 2018	Jun. 30, 2017
Reverse stock split	1-for-20 reverse stock split
Common stock, shares issued	16,641,822	5,592,010	832,235
Common stock, shares outstanding	16,641,822	5,592,010	832,235
Preferred stock, shares issued		2,125,000	125,000
Preferred stock, shares outstanding		2,125,000	125,000
Series A Preferred Stock [Member]
Preferred stock, shares issued	2,500,000
Preferred stock, shares outstanding	2,500,000
Reduced Common Stock [Member]
Common stock, shares issued	832,235
Common stock, shares outstanding	832,235
Reduced Preferred Stock [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued	125,000
Preferred stock, shares outstanding	125,000

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (1,827,634)	$ (1,222,351)

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Dec. 29, 2017	Nov. 29, 2017	Mar. 31, 2018	Dec. 12, 2017	Mar. 31, 2017	Dec. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Preferred stock, shares authorized			5,000,000				5,000,000		5,000,000
Preferred stock, par value			$ 0.001				$ 0.001		$ 0.001
Common stock, shares authorized			195,000,000				195,000,000		195,000,000
Common stock, par value			$ 0.001				$ 0.001		$ 0.001
Offering of common stock units							2,000,000
Shares issued, price per share						$ 0.20
Exercise price of warrants			$ 0.40				$ 0.40
Voting control percentage						63.60%
Officers compensation expense			$ 0		$ 0		$ 398,000	$ 0
Private Offering [Member]
Shares issued, price per share			$ 0.20				$ 0.20
Purchase price of common stock							$ 2,000
Sixteen Investors [Member]
Offering of common stock units				2,759,775
Shares issued, price per share				$ 0.20
Gross proceeds				$ 551,955
Gary Rojewski [Member] | June 2, 2014 to December 27, 2017 [Member]
Number of restricted common shares purchased		2,000,000
Number of restricted common shares purchased amount		$ 2,000
Class A Warrant [Member]
Warrants expiration date							Aug. 31, 2022
Class B Warrant [Member]
Warrants expiration date							Aug. 31, 2022
Class C Warrant [Member]
Warrants expiration date							Aug. 31, 2022
Common Stock [Member]
Offering of common stock units						75,000
Series A Preferred Stock [Member]
Offering of common stock units						125,000
Series A Preferred Stock [Member] | Berkeley's [Member]
Offering of common stock units						2,000,000
Post Reverse Stock Split [Member] | Class A Warrant [Member]
Exercise price of warrants						$ 0.30
Post Reverse Stock Split [Member] | Class B Warrant [Member]
Exercise price of warrants						0.40
Post Reverse Stock Split [Member] | Class C Warrant [Member]
Exercise price of warrants						$ 0.60
Maximum [Member]
Offering of common stock units						3,750,000
Officers compensation expense							$ 400,000
Series A Preferred Stock [Member]
Preferred shares voting rights							The shares of Series A Preferred Stock carry a voting weight equal to 10 shares of common stock per share of Series A Preferred Stock
Series A Preferred Stock [Member] | Berkeley Clinic LC [Member]
Offering of common stock units	2,000,000
Purchase price of common stock	$ 2,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Sep. 29, 2017	Dec. 31, 2017
Shares issued, price per share		$ 0.20
J. Jesky [Member]
Stock issued during period, share, restricted stock award, gross	1,000,000
Mark DeStefano [Member]
Stock issued during period, share, restricted stock award, gross	1,000,000
Shares issued, price per share	$ 0.005
LCNS [Member]
Stock issued during period, share, restricted stock award, gross	2,000,000
Stock issued during period, value, restricted stock award, gross	$ 10,000

Provision for Income Taxes (Det

Provision for Income Taxes (Details Narrative) - USD ($)	9 Months Ended
	Mar. 31, 2018	Dec. 22, 2017	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Deferred tax assets operating loss carryforward	$ 300,223	$ 500,372	$ 427,823
Net operating loss carryforward	$ 1,429,634		$ 1,222,351
Deferred tax asset valuation allowance	100.00%
Operating loss carryforward expiration year	expires commencing in year 2029

Provision for Income Taxes - Sc

Provision for Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details) - USD ($)		9 Months Ended
		Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Expected tax at 35%		$ (211,849)	$ (26,006)
Non-deductible stock based compensation		139,300
Remeasurement of deferred income tax assets from 35% to 21% (a)	[1]	200,149
Increase (decrease) in valuation allowance		(127,600)	26,006
Provision for (benefit from) income taxes
[1]	As a result of the Tax Cuts and Jobs Act enacted on December 22, 2017, the United States corporate income tax rate is 21% effective January 1, 2018. Accordingly, we have reduced our deferred income tax asset relating to our net operating loss carryforward (and the valuation allowance thereon) by $200,149 from $500,372 to $300,223 as of March 31, 2018.

Provision for Income Taxes - 22

Provision for Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details) (Parenthetical) - USD ($)		Dec. 22, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Expected tax rate			35.00%	35.00%
Corporate income tax rate		21.00%	21.00%
Remeasurement of deferred income tax assets	[1]		$ 200,149
Net operating loss carry forward		$ 500,372	$ 300,223		$ 427,823
[1]	As a result of the Tax Cuts and Jobs Act enacted on December 22, 2017, the United States corporate income tax rate is 21% effective January 1, 2018. Accordingly, we have reduced our deferred income tax asset relating to our net operating loss carryforward (and the valuation allowance thereon) by $200,149 from $500,372 to $300,223 as of March 31, 2018.

Provision for Income Taxes - 23

Provision for Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Mar. 31, 2018	Dec. 22, 2017	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Net operating loss carry forward	$ 300,223	$ 500,372	$ 427,823
Less: valuation allowance	(300,223)		(427,823)
Net deferred tax assets

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Mar. 12, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Proceeds from sale of subsidiary	$ 25,000		$ 25,000		$ 25,000
Recovery fees	$ 25,000